Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
about
Structural Basis of Targeting the Exportin CRM1 in CancerCRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons.High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma.Nuclear Export Inhibition for Pancreatic Cancer Therapy.
P2860
Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel reversible selective inh ...... et in colorectal cancer cells.
@ast
Novel reversible selective inh ...... et in colorectal cancer cells.
@en
type
label
Novel reversible selective inh ...... et in colorectal cancer cells.
@ast
Novel reversible selective inh ...... et in colorectal cancer cells.
@en
prefLabel
Novel reversible selective inh ...... et in colorectal cancer cells.
@ast
Novel reversible selective inh ...... et in colorectal cancer cells.
@en
P2093
P2860
P1476
Novel reversible selective inh ...... et in colorectal cancer cells.
@en
P2093
Mingshan Niu
Xuejiao Liu
Yulong Chong
P2860
P304
P356
10.1080/15384047.2015.1047569
P577
2015-05-21T00:00:00Z